Wednesday, April 29, 2020
Senseonics Holdings, Inc. a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced regulatory approval that the Eversense® XL Sensor is no longer contraindicated for MRI which means that the sensor does NOT need to be removed from under the skin during MRI scanning. During scanning the external Eversense Smart Transmitter must still be removed, and once scanning is completed, the transmitter is easily repositioned on the skin.
“Similar to our approved US indication, the European notified body has now approved that Eversense is safe for patients to leave the Eversense XL Sensor in place when they need to have an MRI*,” said Tim Goodnow, PhD, President and CEO of Senseonics. “Now people using Eversense CGM can be confident that they don’t need to worry about an emergency MRI or delay undergoing a scheduled MRI based on their choice of glucose sensors. This is a first for the CGM category as all other sensors are required to be removed during an MRI scan.”
A patient with this device can be safely scanned in an MRI system meeting the following conditions:
The Eversense XL CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure and lasts up to 180 days. Now patients can safely undergo an MRI while still wearing the Eversense XL Sensor – the only CGM sensor with a CE mark that is indicated for this use.